Identifying Molecular Drivers of Lymphomagenesis

Chapter 2 Identifying Molecular Drivers of Lymphomagenesis Jennifer Shingleton, Jennifer ShingletonSearch for more papers by this authorSandeep S. Dave, Sandeep S. DaveSearch for more papers by this author Jennifer Shingleton, Jennifer ShingletonSearch for more papers by this authorSandeep S. Dave, Sandeep S. DaveSearch for more papers by this author Book Editor(s):Owen A. O'Connor, Owen A. O'ConnorSearch for more papers by this authorStephen M. Ansell, Stephen M. AnsellSearch for more papers by this authorJohn F. Seymour, John F. SeymourSearch for more papers by this author First published: 15 March 2023 https://doi.org/10.1002/9781119819950.ch2 AboutPDFPDF ToolsRequest permissionExport citationAdd to favoritesTrack citation ShareShare Abstract Genomic technologies have revolutionized the study of molecular drivers of lymphoma development. These studies have uncovered common as well as disease-specific lymphoma drivers that represent promising therapeutic targets; however, significant barriers to clinical translation still remain. In this chapter, we review the role of NGS in identifying molecular drivers of lymphomagenesis. We survey computational and experimental methods for identifying and validating lymphoma driver genes. We review recurring genetic themes in B- and T-cell lymphomas that reflect normal lymphocyte biology and summarize the genetic landscapes of the most common lymphoma types with their characteristic driver genes and pathways. We discuss various approaches for creating genomic subgroups in diffuse large B-cell lymphoma and the challenges associated with each approach. Finally, we summarize the opportunities and challenges for leveraging genomic subgroups or biomarkers to inform the course of treatment. Precision Cancer Therapies, Volume 1 ‐ Targeting Oncogenic Drivers and Signaling Pathways in Lymphoid Malignancies: From Concept to Practice, I RelatedInformation